EXEL

Exelixis, Inc. News Headlines

$1.63
*  
0.01
0.62%
Get EXEL Alerts
*Delayed - data as of Jan. 23, 2015  -  Find a broker to begin trading EXEL now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
The Surprising Thing Most of 2014's Top 10 Stocks Have in Common
1/11/2015 10:03:02 AM - Motley Fool


Update: My Take On Exelixis' New Agreement With Sobi To Provide COMETRIQ In Europe
1/7/2015 11:50:00 AM - Seeking Alpha


Exelixis, Sobi Extend & Restructure Distribution Agreement For COMETRIQ
1/7/2015 9:08:00 AM - RTT News


3 Biotech Stocks That Could Trounce Gilead Sciences, Inc. in 2015
1/7/2015 9:03:03 AM - Motley Fool


Does This Drug Offer Exelixis Inc. Investors Hope for the Future?
1/2/2015 7:38:03 AM - Motley Fool


3 Biotech Stocks That Could Double in 2015
12/29/2014 6:50:03 AM - Motley Fool


3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
12/23/2014 7:07:02 AM - Motley Fool


The Most Disappointing Clinical Failures in 2014
12/21/2014 7:32:02 PM - Motley Fool


Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
12/17/2014 10:26:00 AM - Investopedia


Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
12/17/2014 10:26:00 AM - Zacks.com


Roche Submitted NDA for Melanoma Combination Drug - Analyst Blog
12/16/2014 6:30:00 PM - Zacks.com


Roche Submitted NDA for Melanoma Combination Drug - Analyst Blog
12/16/2014 6:30:00 AM - Investopedia


Exelixis' Partners File New Drug Application For Cobemetinib - Welcome News But Little Impact
12/16/2014 1:24:00 AM - Seeking Alpha


3 Healthcare Stocks to Watch in 2015
12/15/2014 9:41:03 AM - Motley Fool


Genentech Submits NDA For Cobimetinib With Zelboraf To Treat Advanced Melanoma
12/15/2014 1:27:00 AM - RTT News


Array BioPharma Advances To All Systems Go, Collects $85 Million
12/12/2014 9:13:00 AM - Seeking Alpha


Exelixis' COMET-2 Failure And A Discussion Of Potential Future Cash Flow
12/3/2014 3:51:00 PM - Seeking Alpha


Exelixis Shares Down on COMET-2 Study Results on Cabozantinib - Analyst Blog
12/2/2014 2:29:00 PM - Zacks.com


LifePoint Hospitals To Present At Bank Of America Conference; Webcast At 1:30 PM
12/2/2014 12:32:00 PM - RTT News


Exelixis To Present At Piper Jaffray Conference; Webcast At 1:30 PM ET
12/2/2014 12:32:00 PM - RTT News


Is Exelixis, Inc. Stock Doomed?
12/2/2014 8:14:02 AM - Motley Fool


FDA Lifts Hold On FLXN Study, All''s Well With CPXX Trial, COMET Woes For EXEL
12/2/2014 12:58:00 AM - RTT News


Health Care Down a Bit as Traders Play Defense -- Health Care Roundup
12/1/2014 4:50:00 PM - Dow Jones Business News


Mid-Day Market Update: ON Semiconductor Surges On $1 Billion Buyback Plan; POZEN Shares Slip
12/1/2014 1:43:13 PM - Benzinga


Update: Exelixis Announces Final COMET-2 Data- What Can Shareholders Do?
12/1/2014 1:31:00 PM - Seeking Alpha